Universal Vaccine Against Seasonal Influenza Steps Closer to Reality with the Results of FluGen Phase 2 Clinical Trial
On Tuesday, the vaccine company FluGen announced promising preliminary results from a placebo-controlled, Phase 2 clinical trial of their investigational intranasal influenza vaccine, M2SR, in 99 healthy adults challenged with the A/Belgium/4217/2015, H3N2 strain.